The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1349
ISSUE1349
October 18, 2010
Guanfacine Extended-Release (Intuniv) for ADHD
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Guanfacine Extended-Release (Intuniv) for ADHD
October 18, 2010 (Issue: 1349)
An extended-release oral formulation of guanfacine
hydrochloride (Intuniv – Shire), a selective alpha2A-adrenergic
agonist, has been approved by the FDA for
treatment of attention-deficit/hyperactivity disorder
(ADHD) in children 6-17 years...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.